摘要:氮杂环化合物是目前各类药物及医药中间体的重要组成部分,本次研究方向是构建氨基尿嘧啶类杂环。尿嘧啶是RNA独有的碱基,相同于DNA中的胸腺嘧啶,氨基尿嘧啶类杂环可以通过进一步衍生关环生成嘌呤类化合物。我们用不同的脲和氰乙酸乙酯构建了三个不同的氨基尿嘧啶,根据TLC,LCMS,和HNMR来确定结构,从而能够更加深入了解尿嘧啶类杂环的构建和合成。室温下,搅拌状态下往反应瓶中加入甲醇钠甲醇溶液,接着加入脲,最后加入氰乙酸乙酯,慢慢升温至75度回流8h。降低到室温条件下,将反应液倾入到水中,用浓盐酸调pH至6-7,烘干获得了氨基嘧啶类化合物。在这三个反应中通过更改催化剂、反应时间、反应温度等条件得到反应最优条件,来不断地优化工艺路线,提高其产率,最终达到合成并研究氨基尿嘧啶的目的。48988
毕业论文关键词:尿嘧啶;脲;氰乙酸乙酯;氨基尿嘧啶类杂环
Design and synthesis of nitrogen heterocyclic compounds
Abstract: Nitrogen heterocyclic compounds is an important part of the current all kinds of drugs and pharmaceutical intermediates, the research direction is to build a series of heterocyclic amino uracil. Uracil is unique to the RNA bases, similar to thymine in DNA and amino uracil heterocyclic can be further derived ring closing generation purine compounds. We use different urea and ethyl cyanoacetate construct three different amino uracil, according to TLC, LCMS, and HNMR to determine the structure, so as to more in-depth understanding of uracil heterocyclic construction and synthesis. Room temperature, stirring state to the reaction bottle to add sodium methanol to methanol solution, then adding urea, the final addition of ethyl acetate, slowly warming to 75 degrees reflux 8h. Down to room temperature, the reaction solution is poured into the water, with concentrated hydrochloric acid to 6-7 pH, drying was obtained for the amino - like compounds. In the three reaction through change catalyst, reaction time, reaction temperature and other conditions get the optimal reaction conditions, to constantly optimize the process, improve the yield, and ultimately to achieve the purpose of synthesis and study of amino uracil.
Keywords: uracil; urea; ethyl cyanoacetate; heterocyclic amino uracil
目 录 1
1前言 1
1.1开题依据 1
1.2.1含氮杂环化合物的作用 3
1.2.3尿嘧啶及其衍生物的作用 5
1.2.4氨基尿嘧啶及其衍生物的研究与合成 7
1.3工艺路线的确定 10
1.3.1 6-氨基-1-甲基脲嘧啶的制备 10
1.3.2 1-乙基-6-氨基脲嘧啶的制备 10
1.3.3 4-氨基-3-异丁基嘧啶-2,6-二酮的制备 10
1.4方案论证 11
2实验部分 12
2.1主要实验仪器 12
2.2试剂与原料 12
2.2.1主要试剂名称及物性常数 12
2.2.2原料名称及物性常数 13
2.3实验步骤 15
2.3.1 6-氨基-1-甲基脲嘧啶的制备 15
3核磁共振图谱 18
3.1 6-氨基-1-甲基脲嘧啶